Aminotetraline activators of serotonin receptors
AssigneeAtai Therapeutics, Inc.
InventorsGlenn Short, Robert B. Perni, Tanweer A. Khan
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
Claims18
A compound of Formula (III):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is methyl;
- R2 and R3 are independently H, C1-C6 alkyl, halogen, CN, or OR7;
- R4 and R5 are H;
- R7 is H, C1-C6 alkyl, or C1-C6 fluoroalkyl;
- and
- X is CH or N;
- wherein the compound is not 5,8-dimethoxy-6-methyl-1,2,3,4-tetrahydronaphthalen-2-amine;
- 5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 6-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- 5,7,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
- or 5,6,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine.
A compound of Formula (IV):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is independently H or C1-C6 alkyl;
- R3 is H, C1-C6 alkyl, halogen, CN, OR7 or SR1;
- R4 and R5 are independently H or C1-C6 alkyl;
- R6 and R7 are independently H or C1-C6 alkyl;
- X is CH or N;
- Y is =O or ═NH;
- m is 0, 1, 2 or 3;
- and
- n is 0, 1, 2 or 3.
A compound selected from:
Dependencies are inferred from the claim text.